Research programme: opiate agonists - Alanex/AstraZeneca

Drug Profile

Research programme: opiate agonists - Alanex/AstraZeneca

Alternative Names: Opiate agonists research programme - Alanex/AstraZeneca

Latest Information Update: 23 Aug 2006

Price : $50

At a glance

  • Originator Alanex Corporation
  • Class
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 24 May 1999 Agouron acquired by Warner-Lambert
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
  • 21 Oct 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top